Sanofi’s global head for prostate cancer drug Jevtana is leaving France’s biggest drugmaker.
Zhen Su will pursue a career development opportunity outside of Sanofi and is leaving today, according to an automated reply received in response to an e-mail. Press representatives didn’t respond to repeated attempts for comment.
Sanofi has faced some high-profile departures since the ouster of former Chief Executive Officer Chris Viehbacher seven months ago. The latest is Chief Strategy Officer David-Alexandre Gros, who was also a member of Sanofi’s executive committee: he left earlier this month.
Sanofi said in February that it plans to shrink its cancer operations, eliminating some positions in North America. It stopped operating oncology as a separate division and the unit’s leader, Tal Zaks, quit the company.
Still, Elias Zerhouni, Sanofi’s head of research and development, said in a March interview that the drugmaker plans to invest in cancer, potentially through acquisitions, and will continue growing the business.
Before joining Sanofi in 2013 in Cambridge, Massachusetts, Su was an executive at GlaxoSmithKline Plc.
Some key Viehbacher hires have stayed with the company following the CEO’s ouster, including Zerhouni and Chief Financial Officer Jerome Contamine.